Alzheon CEO Martin Tolar interview with BNN Bloomberg, Canada’s Business News Network reporting on finance and the markets
Listen to our CEO, Martin Tolar, as he discusses the impact on the positive news from the FDA on approving Biogen’s anti-amyloid antibody aducanumab, the first drug that slows the progression of Alzheimer’s. This approval brings hope to patients, and confirms the scientific approach of other anti-amyloid agents such as Alzheon’s oral pill ALZ-801 ,which selectively targets neurotoxic amyloid oligomers.
“The era of Alzheimer’s is here. Alzheimer’s is open for business. There’s one approach that works. And we’re the only oral, but one of the only handful of drugs that could be brought to patients in the next few years.” said Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon.
Use the outline below to jump to the answers you want to hear within this video interview:
Can you just give us your context, as someone who is working in this space, of the importance of this announcement today? [00:47 ]
What do people need to know about this drug [Aduhelm]? [01:18]
Where are you with your own drug? [02:44]
You flirted with a public market offering. Where are you with that thinking and might you do an initial public listing? [03:49]